Summary & Overview
CPT 0526U: CXCL10 Urine Test for Kidney Transplant Monitoring
CPT code 0526U designates a proprietary laboratory test — the CXCL10 Urine Test from One Lambda™ Inc. — that measures urinary CXCL10 via flow cytometry and reports values as pg/mL of creatinine for monitoring kidney transplant patients. This PLA code is specific to one manufacturer’s assay and is used when serial biomarker measurements inform assessment of rejection risk. Nationally, PLA codes like 0526U matter because they identify single-source diagnostics that can affect coverage, laboratory adoption, and clinical workflows for transplant surveillance.
Key payers in this review include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code’s clinical purpose, where the service is typically performed, and which payers are considered. The publication outlines benchmarks and policy-relevant context for proprietary lab tests, summarizes payer coverage considerations and typical billing components, and provides clinical context for use of urinary CXCL10 in transplant monitoring. Data not available in the input is noted where applicable.
Billing Code Overview
CPT code 0526U is a Proprietary Laboratory Analyses (PLA) code that applies exclusively to the CXCL10 Urine Test from One Lambda™ Inc. The test quantifies the chemokine CXCL10 in urine using flow cytometry and reports results as pg/mL of creatinine. It is intended for serial measurement to monitor kidney transplant patients for changes in immune activity associated with transplant rejection risk.
Service Type: Proprietary laboratory diagnostic test (urine biomarker assay)
Typical Site of Service: Clinical laboratory or hospital laboratory
Clinical & Coding Specifications
Clinical Context
A typical patient is a kidney transplant recipient in routine post‑transplant surveillance or with signs/symptoms suggestive of allograft dysfunction (rising serum creatinine, decreased urine output, new proteinuria, or nonspecific systemic symptoms). The transplant nephrologist orders the CXCL10 Urine Test (0526U) to quantify urinary CXCL10 expressed as pg/mL of creatinine using flow cytometry. A urine specimen is collected during an outpatient clinic visit or ambulatory lab draw and sent to the performing laboratory (One Lambda™ Inc.). The laboratory performs the assay and reports a value normalized to urine creatinine; serial measurements over time are compared to prior results to assess trends in immune activation and risk of acute rejection. Results are reviewed by the transplant team and correlated with clinical assessment, serum laboratory studies (including serum creatinine, tacrolimus level), urine studies, and, when indicated, noninvasive imaging or allograft biopsy.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services | Use when test requires substantially greater technical effort or documentation than usual (e.g., additional specimen handling or extended analysis time). |
26 |